Neurogen's aplindore positive in Phase II in Parkinson's and RLS
This article was originally published in Scrip
Neurogen has reported positive top-line results from its Phase IIa trials of its dopamine partial agonist, aplindore, in the treatment of Parkinson's disease and restless legs syndrome (RLS).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.